Edit this postWhat Are Brokerages Saying About Dr. Reddy’s Semaglutide Setback and FY27 Outlook?
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is one of India’s leading global pharmaceutical companies with a broad presence across generics, biosimilars, and active pharmaceutical ingredients. The company’s growth trajectory has recently been influenced by developments surrounding its generic version of Semaglutide in Canada — a key diabetes and weight management drug opportunity.
Brokerage Overview — Diverging Outlooks
Several global brokerages have updated their views on Dr. Reddy’s following regulatory delays for its Canadian Semaglutide launch. While most remain optimistic about long-term fundamentals, short-term earnings adjustments reflect temporary headwinds.
Brokerage Ratings and Key Metrics
| Brokerage | Rating | Target Price (₹) | Key Takeaways |
|---|---|---|---|
| BofA | Buy | 1,600 | Sees FY27 opportunity intact; expects $160mn contribution from Canada; strong filings in 87 countries. |
| Morgan Stanley | Equal-weight | 1,389 | Cautious on delay in Health Canada approval; forecasts $198mn from Canada; competition risk rising. |
| Nomura | Buy | 1,580 | EPS cut by 3–6% for FY26–28; EM markets may offset Canada impact; valuations remain attractive. |
| Citi | Sell | 990 | Expects longer delay (8–12 months); cites multiple pipeline issues and competitive pressure. |
Earnings Outlook and Market Implications
- Approval delay in Canada may shift contribution from FY26 to FY27 but not eliminate the revenue opportunity.
- Analysts project 15% of FY27 EBITDA to stem from Semaglutide across international markets.
- Nomura believes the stock’s correction has priced in the delay, making valuations favorable for long-term investors.
- Rising competition in the Canadian generic market is a short-term overhang, according to Morgan Stanley.
- BofA sees diversified country filings helping cushion Canada-specific setbacks.
SWOT Analysis
- Strength: Strong global presence with multiple filings and robust generic portfolio.
- Weakness: Dependence on regulatory approvals in developed markets like Canada.
- Opportunity: Pipeline across diabetes, oncology, and biosimilars to drive multi-year growth.
- Threat: Delay in high-margin products and increasing generic competition.
Valuation Perspective
Despite near-term headwinds, most brokerages highlight Dr. Reddy’s strong balance sheet, diversified revenue base, and compelling risk-reward trade-off. With FY27 potential intact, the consensus outlook leans towards accumulation on dips rather than panic selling.
Investor Takeaway
Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, who is also a SEBI Regd Investment Adviser, notes that the Semaglutide delay offers a tactical entry window for patient investors. The company’s long-term innovation pipeline and multi-country exposure remain its biggest strengths.
Discover more insights at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
Related Queries on Dr. Reddy’s
- How does the Canada delay impact Dr. Reddy’s FY27 earnings?
- Which brokerages are bullish on Dr. Reddy’s post Semaglutide update?
- What is Dr. Reddy’s valuation outlook for FY26–28?
- Is it the right time to accumulate Dr. Reddy’s stock?
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
